Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 4 Lymphoma, Follicular 4 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, B-Cell 2 Lymphoma 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Dendritic Cell Sarcoma, Interdigitating 1 Burkitt Lymphoma 1 Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 217 Rituximab 110 Etoposide 99 Peripheral Blood Stem Cell Transplantation 93 Vincristine 91 Filgrastim 91 Methotrexate 90 Cytarabine 90 fludarabine phosphate 84 Radiotherapy 67 Doxorubicin 67 Prednisone 66 Dexamethasone 57 Cyclosporine 53 Mycophenolic Acid 52 Whole-Body Irradiation 49 Busulfan 46 Melphalan 44 blinatumomab 43 fludarabine 41 Tacrolimus 41 Antilymphocyte Serum 40 Methylprednisolone 39 merphos 35 Calcium Dobesilate 34 Leucovorin 33 Granulocyte Colony-Stimulating Factor 30 Mercaptopurine 26 dexamethasone acetate 25 dexamethasone 21-phosphate 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Burkitt Lymphoma × veltuzumab × Clear all

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡